Relapsing-Remitting MS (RRMS) Archives

Which patients can initially be treated with platform DMT?

Presented By

Dr Ilaria Addazio, University of Florence, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:44

Positive 4-year efficacy and safety data of ocrelizumab in early MS

Trial

Phase 3, ENSEMBLE

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:36

COVID-19 and MS: lessons learned thus far

Presented By

Prof. Céline Louapre, Sorbonne University, France

Trial

COVISEP

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:52

How and when to make a timely switch to high-efficacy DMT

Presented By

Dr Dalia Rotstein, University of Toronto, Canada

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:08

Study fails to show non-inferiority of rituximab to ocrelizumab

Presented By

Dr Izanne Roos, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:55

Early, non-disabling relapses increase disability accumulation

Presented By

Dr Cyrus Daruwalla, Cambridge University Hospitals, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:13

Chronic active MS lesions respond poorly to anti-CD20 antibodies

Presented By

Dr Pietro Maggi, Saint-Luc University Hospital, Belgium

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:06

Gut microbiota composition associated with disability worsening

Presented By

Dr Ayla Pauwels, Vrije Universiteit Brussel, Belgium

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:26

Cortical lesions predict disease progression and disability accumulation

Presented By

Dr Gian Marco Schiavi, University of Verona, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:40

Dynamic scoring system aids decision to switch MS therapies early

Presented By

Dr Camille Sabathé, French Institute of Health and Medical Research, France

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:31

Stopping DMT: when or if at all?

Presented By

Prof. Ilya Kister (NYU Grossman School of Medicine, NY, USA); Prof. Gavin Giovannoni (Queen Mary University of London, UK)

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:25

Serum NfL as biomarker for suboptimal treatment response

Trial

Cohort study, Swiss MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:07

Predicting autoimmunity in patients treated with alemtuzumab

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:06

Lesion-specific perfusion levels affect myelin loss and repair

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:05

Less thalamic atrophy in patients initiating ocrelizumab earlier

Conference

MS Virtual

Type

Peer-reviewed article

25 November 2020 16:59

No new safety signals in ofatumumab open-label data

Trial

ALITHIOS, ASCLEPIOS I, ASCLEPIOS II, APLIOS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:57

Safety and efficacy of cladribine, glatiramer acetate, and more

Trial

CLASSIC-MS, OPTIMUM

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:55

Therapeutic potential of anti-MOSPD2 monoclonal antibodies

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:49

Retinoid-X receptor agonist promotes remyelination

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:48

NG-specific biomarkers differentiate NMOSD from MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:46

Disease activity during pregnancy in a modern MS cohort

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:27

The maternal perspective: when to stop/resume treatment and risks for progression

Presented By

Dr Emilio Portaccio, University of Florence, Italy

Trial

PRIMS

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 23:28

Challenges in diagnosing and treating progressive MS

Presented By

Dr Xavier Montalban, University of Toronto, Canada

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 23:26

Treatment escalation over induction therapy

Presented By

Dr Emmanuelle Waubant, University of California, San Francisco, USA

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 22:40

Patient awareness about family planning represents a major knowledge gap

Presented By

Prof. Marie D’Hooghe, National MS Center, Belgium

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 21:33

Late-breaking: Ofatumumab versus teriflunomide in relapsing MS

Trial

Phase 3, ASCLEPIOS

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 12:08

Late-breaking: Myelin-peptide coupled red blood cells

Presented By

Prof. Andreas Lutterotti, University of Zurich, Switzerland

Trial

Phase 1, ETIMS-red

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 11:34